Alembic Pharmaceuticals Ltd (APLLTD) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management raises FY27 consolidated revenue growth guidance to 20-25%, signaling strong underlying momentum beyond the current exclusivity-led sales.
- The US branded business is expected to achieve break-even in H1 FY28, which will eliminate the current 150-200 basis point drag on EBITDA margins.
- A new strategic collaboration with DifGen will provide access to over 20 complex generics from FY28, strengthening the US pipeline with high-value products.
Performance Overview
- Alembic Pharmaceuticals reported strong momentum in Q2 FY27, with consolidated revenue growth of 36% year-over-year, driven by exceptional performance across all business segments.
- The US generics business was a standout performer, growing 72% YoY, supported by both the base portfolio and significant contributions from new launches like Bosutinib.
- The India business returned to double-digit growth, with a 14% YoY increase, led by strong performance in chronic and specialty therapies.
- The company announced an expanded strategic collaboration with DifGen Pharmaceuticals, gaining access to a portfolio of over 20 complex generic products for the US market.
- Profitability saw significant improvement, with EBITDA margins expanding by 520 basis points to 22.2% due to operating leverage and a favorable product mix.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.